



Original Article

# Faecal Microbiota Transplantation for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis

Sudarshan Paramsothy,<sup>a,b,c</sup> Ramesh Paramsothy,<sup>d</sup> David T. Rubin,<sup>a</sup> Michael A. Kamm,<sup>e</sup> Nadeem O. Kaakoush,<sup>f</sup> Hazel M. Mitchell,<sup>b</sup> Natalia Castaño-Rodríguez<sup>b</sup>

<sup>a</sup>Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, Illinois, USA <sup>b</sup>School of Biotechnology & Biomolecular Sciences, University of New South Wales, Sydney, NSW, Australia <sup>c</sup>St Vincent's Clinical School, University of New South Wales, Sydney, NSW, Australia <sup>d</sup>Department of Gastroenterology, Liverpool Hospital, Sydney, NSW, Australia <sup>e</sup>Departments of Gastroenterology and Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia <sup>f</sup>School of Medical Sciences, University of New South Wales, Sydney, NSW, Australia

Corresponding author: Natalia Castaño-Rodríguez, MD, MPhil, PhD, School of Biotechnology and Biomolecular Sciences, University of New South Wales, Sydney, NSW 2052, Australia. Tel.: [02] 9385 3514; fax: [02] 9385 1483; email: [n.castanorodriguez@unsw.edu.au](mailto:n.castanorodriguez@unsw.edu.au)

Conference Presentations: 12th Congress of ECCO, Barcelona, 2017; Digestive Disease Week, Chicago, 2017.

## Abstract

**Background:** Faecal microbiota transplantation [FMT] has been investigated as a potential treatment for inflammatory bowel disease [IBD]. We thus performed a systematic review and meta-analysis assessing the effectiveness and safety of FMT in IBD.

**Methods:** A systematic review was conducted until January 2017. Studies were excluded if patients had co-infection or data were pooled across disease subtypes (ulcerative colitis [UC], Crohn's disease [CD], pouchitis). Clinical remission was established as the primary outcome. Pooled effect sizes and 95% confidence intervals were obtained using the random effects model.

**Results:** In all, 53 studies were included [41 in UC, 11 in CD, 4 in pouchitis]. Overall, 36% [201/555] of UC, 50.5% [42/83] of CD, and 21.5% [5/23] of pouchitis patients achieved clinical remission. Among cohort studies, the pooled proportion achieving clinical remission was 33% [95% confidence interval [CI] = 23%–43%] for UC and 52% [95% CI = 31%–72%] for CD, both with moderate risk of heterogeneity. For four RCTs in UC, significant benefit in clinical remission (pooled odds ratios [[P-OR] = 2.89, 95% CI = 1.36–6.13,  $p = 0.006$ ] with moderate heterogeneity [Cochran's  $Q$ ,  $p = 0.188$ ;  $I^2 = 37\%$ ] was noted. Sub-analyses suggest remission in UC improved with increased number of FMT infusions and lower gastrointestinal tract administration. Most adverse events were transient gastrointestinal complaints. Microbiota analysis was performed in 24 studies, with many identifying increased diversity and a shift in recipient microbiota profile towards the donor post-FMT.

**Conclusions:** FMT appears effective in UC remission induction, but long-term durability and safety remain unclear. Additional well-designed controlled studies of FMT in IBD are needed, especially in CD and pouchitis.

**Key Words:** faecal microbiota transplantation; ulcerative colitis; Crohn's disease; pouchitis; inflammatory bowel disease; systematic review; meta-analysis

## 1. Introduction

Faecal microbiota transplantation [FMT] has revolutionised the field of microbial therapeutics. It has proven extremely effective in the treatment of *Clostridium difficile* infection [CDI],<sup>1,2</sup> and is considered to have potential in other conditions where disturbances in the enteric microbiota are implicated in disease pathogenesis, such as the inflammatory bowel diseases [IBD].<sup>3</sup> Although FMT is a simple therapy in practice that was first described in Western medical literature over 50 years ago,<sup>4</sup> and proposed as a treatment strategy for IBD over 25 years ago,<sup>5</sup> it is only in recent years that there has been an exponential growth in patient, media, and research interest.<sup>6</sup> The initial systematic review on the role of FMT in IBD published in 2012 consisted of only nine retrospective reports, deemed of insufficient quality to perform meta-analysis.<sup>7</sup> Within 2 years, an updated systematic review identified 18 studies, including nine cohort studies of FMT in IBD on which a meta-analysis was performed.<sup>8</sup> Since then, the number of available studies has again more than doubled, including the publication of the first four randomised controlled trials [RCTs] of FMT in ulcerative colitis [UC].<sup>9–12</sup>

In this latest systematic review and meta-analysis, we summarise the available literature and evaluate the efficacy of FMT in the various IBD subtypes of UC, Crohn's disease [CD], and pouchitis, by performing meta-analyses on the associated prospective studies.

## 2. Methods

### 2.1. Search strategy

A systematic review was conducted in accordance with the PRISMA,<sup>13</sup> Cochrane,<sup>14</sup> and MOOSE<sup>15</sup> guidelines. We searched five electronic databases [Pubmed, Medline, Cochrane, Biomed Central, and Embase] from inception to the January 4, 2017 using search terms as previously described<sup>7</sup> [Table A1, available as Supplementary data at ECCO-JCC online]. No language limits or any other advance features were used. Major conference proceedings from 2011–2016 were searched to identify abstract publications, including: Digestive Diseases Week [DDW], European Crohn's and Colitis Organisation [ECCO; including 2017], United European Gastroenterology Week [UEGW], American College of Gastroenterology [ACG], and Advances in IBD [AIBD]. References from previous review articles were also searched to identify studies that may have been missed by the above-mentioned searches. The clinicaltrials.gov registry was also searched.

### 2.2. Study selection criteria

#### 2.2.1. Inclusion criteria

Articles were included in this systematic review if they reported on clinical efficacy and/or safety of FMT in inflammatory bowel disease in human subjects. FMT was defined as the infusion of faeces-derived matter and bacteria from a healthy individual[s] into a recipient. Case reports, case series, cohort studies, and RCTs were all included [full text or abstract publications]. For the meta-analyses, however, only cohort studies and RCTs were included.

#### 2.2.2. Exclusion criteria

Studies were excluded if data for particular IBD subtypes [UC, CD, pouchitis] were pooled and not individually reported, due to inherent differences between these conditions. Studies were also excluded if they only included patients who had co-infection with *Clostridium difficile* or other pathogens, or if data on non-infected IBD patients

were not individually reported or able to be extracted. In addition, studies reporting duplicate data were excluded.

#### 2.2.3. Outcome measures

Efficacy of FMT in IBD was assessed as clinical remission [primary outcome] or clinical response as defined by the respective study authors [Tables 1–5]. Where possible, endoscopic [mucosal healing] and histologic data were also extracted. Safety was assessed using reported adverse event and serious adverse event data.

### 2.3. Data extraction

References were imported into a bibliographic database [Microsoft Excel 2015]. Two authors [SP, RP] independently reviewed all articles, initially by title and abstract, then by full text review where relevant, to determine eligibility. Duplicate studies/data were removed manually; when multiple publications related to the same patient group, the most complete data set was included. Eligible studies were categorised based on FMT indication. Data related to the study design and characteristics, treatment groups, and outcome measures were recorded. Where there was disagreement on study eligibility or data extraction, consensus was achieved through discussion [SP, RP, NCR].

### 2.4. Study quality assessment

For eligible cohort studies, the methodological quality was assessed using the Newcastle-Ottawa Scale [NOS]<sup>16</sup> on the standard 9-point scale. Included RCTs were assessed using the Cochrane risk of bias score<sup>17</sup> incorporating random sequence generation, allocation concealment, blinding, incomplete outcome data, and selective reporting.

### 2.5. Statistical analysis

Descriptive statistics were performed on data extracted from all included studies. The efficacy of treatment [clinical remission and/or response] was compared across studies per IBD subtype. For disease subtypes where three or more cohort or RCT studies were included, a meta-analysis was performed. The pooled effect sizes, as well as 95% confidence intervals [CIs], were calculated using both fixed and random effects models. However, the random effects model was the preferred option as it assumes that there is a distribution of true effect sizes rather than one true effect, and it assigns a more balanced weight to each study. For meta-analyses including cohort studies, the effect size refers to the pooled estimate proportion of patients that achieved efficacy. For meta-analyses including RCTs, pooled odd ratios [P-ORs] were calculated by weighting individual ORs by the inverse of their variance.  $p$ -values < 0.05 were considered significant. Heterogeneity was assessed using Cochran's Q test [ $p$ -value < 0.10 is indicative of heterogeneity] and Higgins' test [I<sup>2</sup>] [low heterogeneity: < 25%, moderate heterogeneity: 25–75%, and high heterogeneity: > 75%].<sup>18</sup> Moderator variables including disease severity [mild vs moderate vs severe], route of administration [upper vs lower gastrointestinal FMT infusion], number of infusions (low [1 infusion] vs medium [2–4 infusions] vs high [5–10] vs very high [> 10]), population [paediatric vs adult], preparation of inoculum [fresh vs frozen], FMT donor source [related vs unrelated donor], antibiotic pre-treatment, and bowel lavage, were used to perform subgroup analyses. Sensitivity [leave-one-out] analyses were also conducted to assess statistical robustness. Publication bias was assessed using the Egger's regression asymmetry test as well as funnel plots. Statistical analyses were performed using the Comprehensive Meta-Analysis software V. 3.0 [Biostat, Englewood, NJ, 2004].

**Table 1.** Case reports and case series of faecal microbiota transplantation [FMT] in ulcerative colitis [UC].

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic remission	Histologic remission	Follow-up
Case report	Bennet <i>et al.</i> , 1989 <sup>5</sup>	1	Severe, steroid refractory	NR	Enema	NR	Multiple [not further specified]	NR	Yes [regimen not specified]	NR	1	-	NR	1	6 months
Case report	Borody <i>et al.</i> , 1989 <sup>19</sup>	1	NR	NR	NR	NR	NR	NR	NR	NR	1	-	1	1	3 months
Case report	Borody <i>et al.</i> , 2011 <sup>20</sup>	1	Chronic relapsing UC	NR	NR	NR	NR	NR	NR	NR	0	1	NR	NR	12 years
Case report	Hohmann <i>et al.</i> , 2014 <sup>21</sup>	1	Moderate	Wife & 10-month old child	NR	NR	4	Fresh	No	No	0	0	0	0	NR
Case report	Vandenplas <i>et al.</i> , 2015 <sup>22</sup>	1 [paediatric]	Severe	Related [first 4 infusions: age-related niece, last 3 infusions: older brother]	Colonoscopy first 2 infusions: nasoduodenal.	100 g stool in 100 ml	7 [interval not specified]	Fresh	No	NR	1	-	NR	1	6 months
Case report	Seth <i>et al.</i> , 2016 <sup>23</sup>	1	Moderate [Mayo 9]	Unrelated [brother-in-law]	Colonoscopy	200 g stool in 350 ml saline	3 [every 2 weeks]	Fresh	No	Yes	1	-	1	1	8 months
Case report	Kumagai <i>et al.</i> , 2016 <sup>24</sup>	1 [paediatric]	Severe [PUCAI 85]	Related [mother]	Enema x 2, then nasoduodenal x 4	60 g stool in 250 ml saline	6 [over 10 days]	Fresh	No	NR	0	0	0	0	3 months
Case report	Ni <i>et al.</i> , 2016 <sup>25</sup>	1	Moderately steroid-dependent [Mayo 9]	Related [father]	Percutaneous endoscopic caecostomy	100 g stool in 250 ml saline	> 50 [daily for 1 month then 2 x week for 3 months]	Fresh	No	Yes	1 [Mayo 0]	-	1 [Mayo 0]	NR	12 months
Case report	Shimzu <i>et al.</i> , 2016 <sup>26</sup>	1 [paediatric]	Severe steroid dependent	Related [father]	Colonoscopy x 1 then enemas	Stool diluted in 250 ml saline	16 [daily for first 5 days, then every 2-4 weeks over 10 months]	Fresh	No	Yes	1 [PUCAI 0]	-	0	0	10 months

Table 1. Continued

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic remission	Histologic remission	Follow-up
Case series	Borody <i>et al.</i> , 2001 <sup>27</sup>	3	Active colitis, severe symptoms	NR	Enema	Stool diluted in 200 ml infusion	5 [daily for 5 days]	Fresh	Vancomycin 500mg bd, metronidazole 400 mg bd, rifampicin 150 mg bd for 7–15 days	NR	3/3 [100%]	-	3/3 [100%]	NR	8–16 months
Case series	Borody <i>et al.</i> , 2003 <sup>28</sup>	6	Active, not further specified	Recipient-identified [related & unrelated]	Enema	200–300 g stool in 200–300 ml saline	5, [daily for 5 days]	Fresh	Vancomycin 500 mg bd + metronidazole 400 mg bd + rifampicin 150 mg bd for 7–10 days	Yes	6/6 [100%]	-	6/6 [100%]	6/6 [100%]	1–13 years
Case series	Borody <i>et al.</i> , 2012 <sup>29</sup>	62	Active, not further specified	NR	NR	NR	NR	NR	NR	NR	42/62 [68%] [0–1 on modified Powell-Tuck index]	57/62 [92%] [> 2-point drop in Powell-Tuck index]	12/21 [57%]	12/21 [57%]	NR
Case series	Shah <i>et al.</i> , 2012 <sup>30</sup>	16	NR	NR	NR	NR	NR	NR	NR	NR	NR	8/16 [50%] [avoid surgery or medications]	NR	NR	NR
Case series	Brandt <i>et al.</i> , 2013 <sup>31</sup>	11	NR	NR	NR	NR	NR	NR	NR	NR	NR [safety study]	NR	NR	NR	Mean 14.7 months [range 7–31]

NR, not recorded; bd, twice daily; PUCAL, paediatric ulcerative colitis activity index.

Table 2. Cohort studies of faecal microbiota transplantation [FMT] in ulcerative colitis.

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic remission	Histologic remission	Follow Up	NOS Total
Cohort	Angelberger et al., 2013 <sup>32</sup>	5	Moderate-severe [Mayo ≥ 6]	Recipient-identified but first degree-relatives excluded	Nasojejunal enema combined	Median 24 g stool in 250 ml saline for nasojejunal infusion, median 20 g stool in 100 ml saline for enema	3 [daily for 3 days]	Fresh	Metronidazole 500 mg bd and probiotic [Yomogi or Ommbiotic] for 5–10 days before FMT	Yes	0 [Mayo ≤ 2, no subscore > 1]	1/5 [20%] [Mayo drop ≥ 3 and ≥ 30%, along with drop in bleeding subscore ≥ 1 or bleeding subscore ≤ 1]	NR	NR	12 weeks	5
Cohort	Kump et al., 2013 <sup>33</sup>	6	Moderate-severe [Mayo 8–11]	Unrelated	Colonoscopy [TI + colon]	100–150 g stool in 200–350 ml	Single	Fresh	No	Yes	0 [Mayo ≤ 2]	2/6 [33%] [Mayo drop ≥ 3]	NR	NR	3 months	5
Cohort	Kunde et al., 2013 <sup>34</sup>	10 [paediatric]	Mild-moderate [PUCAI 15–65]	Recipient-identified [related & unrelated]	Enema	Average 90 g stool [range 70–113 g] in 4 x 60 ml saline	5 [daily for 5 days]	Fresh	No	No	3/9 [33%] at 1 and 4 weeks [PUCAI < 10]	7/9 [78%] at 1 month [PUCAI drop > 15]	NR	NR	4 weeks	6
Cohort	Cui et al., 2015 <sup>35</sup>	15 [data on 14]	Moderate-severe [Montreal] Steroid-dependent	Recipient-identified [related & unrelated]	Midgut through gastroscop	150–200 ml infusion	1–2, [1 week apart]	NR	No	NR	4/14 [29%] [Montreal 0]	8/14 [57%] [Montreal improvement ≥ 1] & discontinuation of steroids	NR	NR	> 3 months	5
Cohort	Damman et al., 2015 <sup>36</sup>	7	Mild-moderate [UCDAI 3–10]	Recipient-identified [1 related, rest unrelated]	Colonoscopy	175–290 ml of stool mixture [1 g stool:2–3 ml saline]	Single	Fresh	No	Yes	1/7 [14%] at 4 weeks [UCDAI ≤ 2 & no subscore > 1]	1/7 [14%] at 4 weeks [UCDAI drop ≥ 3]	NR	1/7 [14%] at 4 weeks	3 months	6
Cohort	Karolewska-Bohenek et al., 2015 <sup>37</sup>	4 [paediatric]	Moderate-severe	Unrelated	Gastroscopy	50 ml infusion	8 [daily first 5 days, alternate days in second week]	NR	No	NR	0	4/4 [100%]	NR	NR	4 weeks	4

Table 2. Continued

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic remission	Hisrologic remission	Follow Up	NOS Total
Cohort	Kellermayer <i>et al.</i> , 2015 <sup>38</sup>	3 [paediatric]	Immunotherapy-dependent but controlled mucosal disease at study commencement [Mayo 0-1]	Unrelated	Colonoscopy followed by enemas	50 g stool in 250 ml saline; 60-250 ml delivered	22-30 [daily for fortnight, thrice weekly for fortnight, then weekly for 6-12 weeks]	Frozen	No	Yes	3/3 [100%]	-	3/3 [100%]	3/3 [100%]	3 months	3
Cohort	Kump <i>et al.</i> , 2015 <sup>39</sup>	17, 10 controls [triple antibiotic therapy]	Chronic active [Mayo ≥ 4]	NR	Colonoscopy [initially right colon, then left colon on subsequent infusions]	NR	5 [fortnightly infusions]	NR	Triple therapy [not specified] for 10 days	Yes	FMT: 4/17 [24%], control: 0 [Mayo ≤ 2]	FMT: 10/17 [59%], control: 2/10 [20%] [Mayo drop ≥ 3]	NR	NR	90 days	6
Cohort	Scaldaferri <i>et al.</i> , 2015 <sup>40</sup>	8, 7 controls	Mild-moderate [partial Mayo ≥ 4, endoscopic Mayo ≥ 1]	Recipient-identified	NR	200 ml of faecal slurry	3 [interval not specified]	NR	Not specified	Yes	FMT: 3/8 [38%], control: 2/7 [29%] [partial Mayo ≤ 2, all subscores ≤ 1]	FMT: 4/8 [50%], control: 2/7 [29%] [partial Mayo drop ≥ 2]	33% [Mayo 0 at Week 6]	NR	12 weeks	7
Cohort	Suskind <i>et al.</i> , 2015 <sup>41</sup>	4 [paediatric]	Mild-moderate [PUCAI]	NR	Nasogastric	30 g stool in 100 ml saline	Single	Fresh	Rifaximin 200 mg tds for 3 days, omeprazole day before and day of FMT	Yes	0 [PUCAI < 10]	0	NR	NR	12 weeks	6
Cohort	Vermeire <i>et al.</i> , 2016 <sup>42</sup>	8	Moderate-severe; refractory, failed immunotherapy and anti-TNF	Unrelated & related	Nasogastric 3, rectal tube 5	200 g stool in 400 ml	2 [daily for 2 days]	Fresh	No	Yes	2/8 [25%]	NR	2/8 [25%] [Mayo endoscopy subscore ≤ 1]	NR	8 weeks	5

Table 2. Continued

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic remission	Histologic remission	Follow Up	NOS Total
Cohort	Wei <i>et al.</i> , 2015 <sup>43</sup>	11	Mild-moderate [Mayo 2-10]	Unrelated	Colonoscopy	60 g stool in 350 ml saline	Single	Fresh	Vancomycin 500 mg bd for 3 days before FMT	Yes	8/11 [73%] [Mayo < 2]	NR	NR	NR	4 weeks	4
Cohort	Ren <i>et al.</i> , 2015 <sup>44</sup>	7	Severe [Mayo ≥ 10]	Relatives or healthy volunteers	Gastroscopy or colonoscopy or combined gastroscopy & colonoscopy	Gastroscopy, 100-200 ml; colonoscopy, 200-300 ml	1-3 infusions [5 pts x 1, 1 pt x 2, 1 pt x 3]	Fresh	No	No	5/7 [71%] [Day 30] [partial Mayo ≤ 2, subscores ≤ 1]	7/7 [100%] [partial Mayo drop ≥ 3 or 30% drop]	NR	NR	median 90 days, range 30-210 days	5
Cohort	Karakan <i>et al.</i> , 2016 <sup>45</sup>	14	Steroid-dependent or non-responsive	NR	Colonoscopy	NR	1-6 [interval not specified]	NR	NR	Yes	6/14 [43%]	11/14 [78.5%]	NR	NR	3-18 months	4
Cohort	Goyal <i>et al.</i> , 2016 <sup>46</sup>	12 [paediatric]	Mild-moderate [PUCAI < 65]	Recipient-identified [related & unrelated]	Both gastroscopy/jejunoscopy [20-30 ml] and colonoscopy [200-250 ml] in Tl/cecum	150 g stool in 250 ml saline	Single	Fresh	Metronidazole/ vancomycin for 5 days, ceasing 48 before FMT	Yes	0 [PUCAI < 10]	2/12 [17%] [PUCAI drop ≥ 15]	NR	NR	6 months	6
Cohort	Laszlo <i>et al.</i> , 2016 <sup>47</sup>	4	Moderate-severe	Related [family member]	Colonoscopy	150 ml faecal suspension diluted in 400-425 ml saline	Single	Fresh	No	Yes	4/4 [100%]	-	2/4 [50%]	NR	5 months	5
Cohort [RCT for pectin, FMT in both arms]	Wei <i>et al.</i> , 2016 <sup>48</sup>	20 [10 FMT alone; 10 FMT + 5 days oral pectin]	Mild-moderate [Mayo 2-10]	Unrelated	Colonoscopy	60 g stool in 500 ml saline	Single	Fresh	Vancomycin 500 mg bd for 3 days before FMT	Yes	7/20 [35%] [3/10 FMT, 4/10 FMT + pectin] [Mayo ≤ 2]	13/20 [65%] [7/10 FMT, 6/10 FMT + pectin] [Mayo drop > 30%, 1 point drop in tarry stools or increase > 16 points in IBDQ]	NR	NR	12 weeks	5

Table 2. Continued

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic remission	Histologic remission	Follow Up	NOS Total
Cohort [data from ongoing RCT]	Pai <i>et al.</i> , 2016 <sup>49</sup>	2 [paediatric]	Active	Unrelated	Enemas	NR	12 [biweekly for 6 weeks]	Frozen	NR	NR	0	0	NR	NR	NR	7
Cohort	Jacob <i>et al.</i> , 2016 <sup>50</sup>	20	Active [Mayo ≥ 3, endoscopic subscore ≥ 1]	Unrelated multidonor [2-donor concentrate]	Colonoscopy [TI + right colon]	120 ml infusion	Single	Frozen	No	Yes	3/20 [15%] [Mayo ≤ 2, no subscore > 1]	7/20 [35%] [Mayo drop ≥ 3 and bleeding subscore ≤ 1]	2/20 [10%] [Mayo endoscopy subscore 0]	NR	4 weeks	6
Cohort	Nishida <i>et al.</i> , 2016 <sup>51</sup>	41	Mild-moderate [Mayo 3-9, endoscopic subscore ≥ 1]	Related [family member]	Colonoscopy [caecum]	150-200 g stool in 500 ml saline	Single	Fresh	No	Yes	0 [Mayo ≤ 2, no subscore > 1]	11/41 [27%] [Mayo drop ≥ 3 and/or Mayo clinical score drop ≥ 2 with rectal bleeding subscore decrease ≥ 1]	NR	NR	8 weeks	6
Cohort	Zhang <i>et al.</i> , 2016 <sup>52</sup>	19	Moderate-severe [Mayo ≥ 6]	NR	Midgut through gastroscop	150-200 ml infusion	Single	Fresh	No	NR	2/19 [11%] [Mayo ≤ 2, no subscore > 1]	11/19 [58%] [Mayo drop ≥ 3 or ≥ 30%, along with drop in bleeding subscore ≥ 1 or bleeding subscore ≤ 1]	NR	NR	≥ 3 months	5
Cohort	Grewal <i>et al.</i> , 2016 <sup>53</sup>	17	Moderate-severe, steroid-dependent	NR	NR	NR	7 [2 infusions 2 weeks apart, then 5 infusions every 4 weeks]	NR	NR	NR	15/17 [88%] [Week 4] 10/17 [59%] at 1 year with steroid cessation	NR	NR	NR	12 months	5



Table 2. Continued

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic remission	Histologic remission	Follow Up	NOS Total
Cohort [open-label extension cohort of RCT placebo arm]	Paramsothy <i>et al.</i> , 2017 <sup>11</sup>	37	Mild-moderate [Mayo 4-10]	Unrelated multidonor [3-7 donors/infusion]	Colonoscopy followed by enemas	37.5 g stool in 150 ml saline	40 [5/week for 8 weeks]	Frozen	No	No	17/37 [46%] [steroid-free Mayo subscore ≤ 1 for bleeding & stool frequency combined]	NR	8/37 [22%] [steroid-free Mayo endoscopy subscore 0]	NR	8 weeks post FMT [total 16 weeks]	5
Cohort	Ishikawa <i>et al.</i> , 2017 <sup>54</sup>	17, 19 controls [triple antibiotic therapy]	Active [Lichtiger Clinical Activity Index ≥ 5 or endoscopic Mayo subscore ≥ 1]	Recipient-identified [related & unrelated]	Colonoscopy	150-250 g stool in 350-500 ml saline	Single	Fresh	Amoxicillin 1500 mg, fosfomycin 3000 mg, metronidazole 750 mg daily for 2 weeks till 2 days before FMT	Yes	FMT: 9/17 [53%], control: 3/19 [16%] [CAI ≤ 3]	FMT: 14/17 [82%], control: 13/19 [68%] [CAI < 10 & drop ≥ 3]	NR	NR	4 weeks	9

NOS, Newcastle-Ottawa Scale; NR, not recorded; bd, twice daily; PUCAI, Paediatric Ulcerative Colitis Activity Index; RCT, randomised controlled trials; tds, three times daily; TNF, tumour necrosis factor; IBDQ, Inflammatory Bowel Disease Questionnaire.

**Table 3.** Randomised controlled trials of faecal microbiota transplant [FMT] in ulcerative colitis.

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic lavage	Bowel lavage	Primary endpoint	Clinical remission	Clinical response	Endoscopic remission	Endoscopic response	Histologic remission up	Follow-up
DBRCT	Moayeddi <i>et al.</i> , 2015 <sup>9</sup>	75: 38 FMT, 37 controls	Mild-severe, [Mayo 4-12]	Unrelated	Enema	50g stool in 50 ml infusion	6 [weekly]	Frozen 21, fresh 15, combination fresh & frozen 1	No	No	Clinical and endoscopic remission Mayo < 3 with endoscopic Mayo 0 9/38 [24%] vs 2/37 [5%], <i>p</i> = 0.03	9/38 [24%] vs 2/37 [5%], <i>p</i> = 0.03 [Mayo < 3] <i>p</i> = 0.16 [Mayo endoscopy drop ≥ 3] subscore 0]	15/38 [39%] vs 9/37 [24%], <i>p</i> = 0.16 [Mayo endoscopy drop ≥ 3]	9/38 [24%] vs 2/37 [5%], <i>p</i> = 0.03 [Mayo endoscopy drop ≥ 3] subscore 0]	NR	7 FMT, 1 placebo	7 weeks
	Rossen <i>et al.</i> , 2015 <sup>10</sup>	48: 23 FMT, 25 control autologous stool	Mild-moderate [SCCAI 4-11]	Unrelated & related	Nasoduodenal	Minimum 60 g stool in 500 ml	2 [3 weeks apart]	Fresh	No	Yes	Clinical remission and endoscopic improvement SCCAI ≤ 2 in combination with ≥ 1 point drop in combined Mayo endoscopic score [rectum & sigmoid], 7/23 [30%] vs 5/25 [20%], <i>p</i> = 0.51	7/23 [30%] vs 8/25 [32%], <i>p</i> = NS [SCCAI ≤ 2]	11/23 [48%] vs 13/25 [52%], <i>p</i> = NS [SCCAI drop ≥ 1.5]	NR	8/23 [35%] vs 9/25 [36%], <i>p</i> = NS (≥ 1 point drop in combined Mayo endoscopic score [rectum & sigmoid])	NR	12 weeks

Table 3. Continued

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic lavage	Bowel lavage	Primary endpoint	Clinical remission	Clinical response	Endoscopic remission	Endoscopic response	Histologic remission	Follow-up
DBRCT	Paramsothy et al., 2017 <sup>11</sup>	81: 41 FMT, 40 controls	Mild-moderate [Mayo 4–10]	Unrelated multi-donor [3–7 donors/infusion]	Colonoscopy followed by enemas	37.5 g stool in 150 ml saline infusion	40 [5/week for 8 weeks]	Frozen	No	Yes	Steroid-free clinical remission and endoscopic improvement, Mayo $\leq 2$ , all subscores $\leq 1$ , $\geq 1$ point drop in endoscopy subscore, off steroids 11/41 [27%] vs 3/40 [8%], $p = 0.02$	18/41 [44%] vs 8/40 [20%], $p = 0.02$	22/41 [54%] vs 9/40 [23%], $p = 0.01$	5/41 [12%] vs 3/40 [8%], $p = NS$	13/41 [32%] vs 4/40 [10%], $p = 0.02$	NR	8 weeks post FMT [total 16 weeks]
DBRCT	Costello et al., 2017 <sup>12</sup>	73: 38 control autologous stools	Mild-moderate [Mayo 3–10]	Unrelated multi-donor [3–4 donors/infusion]	Colonoscopy followed by enemas	NR	3 [3/week]	Frozen	No	Yes	Steroid-free remission, Mayo $\leq 2$ , endoscopic subscore $\leq 1$ , off steroids 12/38 [32%] vs 3/35 [9%], $p = 0.02$	19/38 [50%] vs 6/35 [17%], $p < 0.01$	21/38 [55%] vs 7/35 [20%], $p < 0.01$	21/38 [55%] vs 6/35 [17%], $p < 0.01$	NR	NR	8 weeks

DBRCT, double-blind randomised placebo-controlled trial; NR, not recorded; SCCAI, Simple Clinical Colitis Activity Index; NS, not significant.

**Table 4.** Case Reports and Cohort Studies of FMT in Crohn's Disease

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic remission	Histologic remission	Follow-up	NOS total
Case report	Borody <i>et al.</i> , 1989 <sup>19</sup>	1	NR	NR	NR	NR	NR	NR	NR	NR	1	-	NR	NR	4 months	-
Case report	Swaminath <i>et al.</i> , 2014 <sup>55</sup>	1	Patchy colitis, severe from 11 to 22 cm	Partner	Enema	NR	5 [daily for 5 days]	Fresh	NR	NR	0 [worsening of colitis symptoms with FMT]	0 [worsening of colitis symptoms with FMT]	NR	NR	3 weeks, near resolution of bleeding and diarrhoea with topical 5-ASA	-
Case report	Gordon <i>et al.</i> , 2014 <sup>56</sup>	1	Severe, HBI 30	partner	NR	NR	Daily, number not specified	Fresh	Vancomycin for previous <i>Clostridium difficile</i> infection	NR	0	1 [HBI drop 30 to 7]	NR	NR	Relapse at 6 months, commenced azathioprine	-
Case report	Kao <i>et al.</i> , 2014 <sup>57</sup>	1	Moderate-severe, HBI 12	Unrelated	Colonoscopy	400 ml of 1-4 stool; saline	Single	Fresh	7-day course of ciprofloxacin & metronidazole till 2 days before FMT	Yes	1 [HBI 0]	-	1 complete mucosal healing	1	4 weeks	-
Cohort	Kahn <i>et al.</i> , 2014 <sup>58</sup>	8	Active, HBI > 6	Unrelated	Colonoscopy	NR	Single	NR	NR	Yes	NR [safety study]	NR	NR	NR	1 week	4
Cohort	Cui <i>et al.</i> , 2015 <sup>59</sup>	30	Moderate-severe, HBI > 6	Unrelated & related	Midgut through gastroscopie	150-200 ml infusion	Single	Fresh or frozen	No	yes	23/30 [76.7%] [HBI < 5]	26/30 [86.7%] [HBI drop > 3]	NR	NR	6-15 months	4
Cohort	Suskind <i>et al.</i> , 2015 <sup>60</sup>	9 [paediatric]	Mild-moderate [PCDAI 10-29]	Related [parent]	Nasogastric	30 g stool in 100-200 ml saline	Single	Fresh	Rifaximin 200 mg tds for 3 days, omeprazole day before and day of FMT	Yes	Week 2: 7/9 [78%], Weeks 6 & 12: 5/9 [56%] [PC-DAI < 10]	NR	NR	NR	12 weeks	6
Cohort	Vermeire <i>et al.</i> , 2016 <sup>42</sup>	6	Moderate-severe	Unrelated & related	Nasogastric	200 g stool in 400 ml saline	2 [daily for 2 days]	Fresh	No	Yes	0	NR	0	NR	8 weeks	5
Cohort	Wei <i>et al.</i> , 2015 <sup>43</sup>	3	Active, CDAI 150-400	Unrelated	Nasogastric [2] colonoscopy [1]	60 g stool in 350 ml saline	Single	Fresh	Vancomycin 500 mg bd for 3 days before FMT	Yes	0	Mean CDAI drop from 345 to 135	NR	NR	4 weeks	5
Cohort	Vaughn <i>et al.</i> , 2016 <sup>61</sup>	19	Active, HBI ≥ 5	Unrelated	Colonoscopy	50 g stool in 250 ml solution	Single	Frozen	No	Yes	10/19 [53%] [HBI < 5 at Week 4]	11/19 [58%] [HBI drop ≥ 3 at Week 4]	NR	NR	2.6 weeks	6

Table 4. Continued

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic remission	Histologic remission	Follow-up	NOS total
Cohort	Goyal <i>et al.</i> , 2016 <sup>46</sup>	4 [paediatric]	Mild-moderate, PCDAI < 40	Recipient-identified [related & unrelated]	Both duodenoscopy and jejunoscopy [20–30 ml] and colonoscopy [200–250 ml]	150 g stool in 250 ml saline	Single	Fresh	Metronidazole/ vancomycin for 5 days, ceasing 48 h before FMT	yes	2/4 [50%] PC-DAI < 10 or normalisation of lactoferrin/calprotectin	3/4 [75%] PCDAI drop of $\geq 12.5$	NR	NR	6 months	4

NOS, Newcastle-Ottawa Scale; 5-ASA, 5-aminosalicylic acid; NR, not recorded; HBI, Harvey-Bradshaw Index; PCDAI, Paediatric Crohn's Disease Activity Index; tds, three times daily; bd, twice daily.

### 3. Results

#### 3.1. Study characteristics

A total of 6806 articles were identified in the search, which included 261 internal and external duplicates [Figure 1]. Titles and abstracts of 6545 articles were screened and only 109 were deemed potentially eligible, of which 107 were available for review. A total of 53 articles or abstracts of FMT in IBD were deemed to satisfy the study selection criteria and were included in the final analysis, of which three included more than one IBD subtype. This included 41 articles or abstracts assessing FMT in UC and reporting on 555 UC patients, 11 in CD reporting on 83 CD patients, and four in pouchitis reporting on 23 patients.

#### 3.2. Study quality

The methodological quality of the included cohort studies and RCTs are outlined in the Appendix [Tables A2, A3, available as Supplementary data at ECCO-JCC online]. Only four cohort studies included a control group, with a mean NOS score of 5 [range 3 to 9] out of 9. The risk of bias in the included randomized trials was low [Costello *et al.*, 2017,<sup>12</sup> presented in abstract form but yet to undergo full publication peer review]. All significant results obtained through the meta-analyses remained significant in sensitivity analyses, inferring statistical robustness.

#### 3.3. Ulcerative colitis

A total of 41 studies were identified assessing FMT in UC (nine case reports, five case series, 24 prospective cohort studies [20 uncontrolled, four controlled] and four RCTs), reporting on 555 UC patients [Tables 1-3].

Overall, 36% [201/555] of UC patients achieved clinical remission during follow-up. Among the 24 cohort studies included in the meta-analysis [Figure 2], which comprised 307 individuals, the pooled proportion of patients that achieved clinical remission was 33% [95% CI = 23–43%] for UC, with a moderate risk of heterogeneity [Cochran's Q,  $p = 0.001$ ;  $I^2 = 54\%$ ] [Table A4, available as Supplementary data at ECCO-JCC online] and no publication bias [Table A5, available as Supplementary data at ECCO-JCC online]. The pooled proportion of patients that achieved clinical response was 52% [95% CI = 40–64%] in a meta-analysis that included 234 individuals from 20 cohort studies [Figure A1, available as Supplementary data at ECCO-JCC online]; a moderate level of heterogeneity [Cochran's Q,  $p = 0.001$ ;  $I^2 = 58\%$ ] and no publication bias was observed in this meta-analysis [Table A5].

Meta-analysis including four RCTs of FMT in UC [Figure 3], which comprised a total of 140 FMT-treated individuals, showed that FMT was significantly associated with clinical remission in these patients [P-OR = 2.89, 95% CI = 1.36–6.13,  $p = 0.006$ ]. Heterogeneity was moderate in this meta-analysis [Cochran's Q,  $p = 0.188$ ;  $I^2 = 37\%$ ] with no publication bias [Table A5]. A significant association was also found between FMT and clinical response in UC patients [P-OR = 2.48, 95% CI = 1.18–5.21,  $p = 0.016$ ] [Figure A2, available as Supplementary data at ECCO-JCC online], with a moderate level of heterogeneity [Cochran's Q,  $p = 0.102$ ;  $I^2 = 52\%$ ] and no publication bias [Table A5].

Interestingly, sensitivity analyses showed that on removal of the RCT by Rossen *et al.*<sup>10</sup> [which in contrast to the other studies used only two infusions and administered them via an upper gastrointestinal infusion] the association between FMT and clinical remission in UC patients was highly significant [P-OR of 4.05, 95% CI = 2.08–7.89,  $p = < 0.001$ ; Cochran's Q,  $p = 0.783$ ;  $I^2 = 0\%$ ] [Figure A3, available as Supplementary data at ECCO-JCC online]. Similarly, the association

**Table 5. Case Reports and Cohort Studies of FMT in Pouchitis**

Study type	Author	Patients	Severity	Donor	Route	Dosage [volume]	Frequency [number of infusions]	Fresh vs frozen	Pre-antibiotic	Bowel lavage	Clinical remission	Clinical response	Endoscopic outcomes	Histologic outcomes	Follow-up	NOS total
Case report	Fang <i>et al.</i> , 2016 <sup>62</sup>	1 [primary diagnosis: UC]	Chronic antibiotic-refractory pouchitis [mPDAI 10; clinical mPDAI 6]	NR	Pouchoscopy	Stool diluted in 250 ml saline	Single	Fresh	Antibiotics ceased 48 h before FMT	NR	1 [clinical PDAI 0]	-	NR	NR	6 months	-
Cohort	Landy <i>et al.</i> , 2015 <sup>63</sup>	8 [primary diagnosis: UC]	Chronic pouchitis [PDAI > 7]	Unrelated & related	Nasogastric	30 g stool in 50 ml saline	Single	Fresh	No, antibiotic-free for 2 weeks before FMT	NR	0	2/8 [25%] [PDAI drop ≥ 3]	NR	NR	4 weeks	6
Cohort	El-Nachef <i>et al.</i> , 2016 <sup>64</sup>	9 [4 weeks' data on 7] [primary diagnosis: NR]	NR	Unrelated	Pouchoscopy	NR	Single	Frozen	NR	NR	NR	5/7 [71%] [global symptom improvement]	NR	NR	4 weeks	5
Cohort	Stallmach <i>et al.</i> , 2016 <sup>65</sup>	5 [primary diagnosis: NR]	Chronic antibiotic-refractory pouchitis [PDAI 9-14]	Unrelated	UGI [jejunum] endoscopy	75 g stool in 200 ml saline	1-7 [at 3-4-week intervals]	Fresh for initial; either frozen or fresh for subsequent infusions	Not part of FMT protocol. All patients failed ≥ 3 cycles of metronidazole and ciprofloxacin +/- rifaximin	NR	4/5 [80%]	5/5 [100%]	Endoscopic remission: 1/5 [20%] endoscopic response: 5/5 [100%] [based on endoscopy subscore on PDAI]	0 [histology subscore of 0 on PDAI]	3 months	6

NOS, Newcastle-Ottawa Scale; PDAI, Perianal Disease Activity Index; UC, ulcerative colitis; NR, not recorded; UGI, upper gastrointestinal.




Figure 1. Flow diagram of search strategy.

between FMT and clinical response in these patients when the RCT by Rossen *et al.*<sup>10</sup> was removed showed a higher P-OR of 3.39 [95% CI = 1.90–6.04,  $p < 0.001$ ; Cochran's  $Q$ ,  $p = 0.442$ ;  $I^2 = 0\%$ ] [Figure A4, available as Supplementary data at ECCO-JCC online].

### 3.4. Crohn's disease

Eleven studies in CD [four case reports, seven prospective uncontrolled cohort studies] reporting on 83 CD patients were included [Table 4]. Overall 50.5% [42/83] of CD patients achieved clinical remission during follow-up. Among the six cohort studies included in the meta-analysis [Figure 4], comprising 71 individuals, the pooled proportion of CD patients that achieved clinical remission was 52% [95% CI = 31–72%] with a moderate risk of heterogeneity [Cochran's  $Q$ ,  $p = 0.063$ ;  $I^2 = 52\%$ ]; however, publication bias was observed in this meta-analysis [Table A5]. A meta-analysis including four cohort studies [Figure A5, available as Supplementary data at ECCO-JCC online], which comprised 59 individuals, showed that the pooled estimate proportion of patients that achieved clinical response was 63% [95% CI = 30–88%]. Moderate heterogeneity was observed in this meta-analysis [Cochran's  $Q$ ,  $p = 0.016$ ,  $I^2 = 71\%$ ]; no publication bias was detected [Table A5].

### 3.5. Pouchitis

Three prospective uncontrolled cohort studies and one case report assessing FMT in pouchitis were identified [Table 5], reporting on 23 patients. Two of the cohort studies used a single FMT infusion; no patients achieved clinical remission, with 2/8 [25%] achieving clinical response in one study<sup>63</sup> and, in the other study, 5/7 [71%]


had global symptom improvement [not defined] at 1 month.<sup>64</sup> In the only study that allowed for multiple FMT infusions, 4/5 patients achieved clinical remission [with the other patient achieving clinical response].<sup>65</sup> We did not perform a pouchitis meta-analysis as only three small cohort studies were identified which had differing endpoints and conflicting outcomes.

### 3.6. Endoscopic data


Specific endoscopic outcomes were reported in the four RCTs and six of the 24 cohort studies of FMT in UC [Table 2]. Accounting for differing definitions of endoscopic outcomes, endoscopic remission or endoscopic response rates of 24–55% with allogeneic FMT vs 5–17% with control [placebo or autologous FMT] [mean difference 26.3%  $\pm$  9.9,  $p$ -value: 0.057] were noted in the RCTs involving multiple lower gastrointestinal FMT infusions,<sup>9,11,12</sup> whereas no difference was noted in endoscopic response between allogeneic or autologous FMT administered by two nasoduodenal infusions [35% vs 36%]<sup>10</sup> [Table 3]. Only one study in CD reported endoscopic outcomes,<sup>42</sup> with none of six patients achieving endoscopic remission. In the one pouchitis study that reported endoscopic outcomes, all five patients had an endoscopic response and one patient [20%] achieved endoscopic remission after 1–7 FMT infusions.<sup>65</sup>

### 3.7. Histologic data

Only a small number of studies in UC reported histologic outcomes. Post hoc analysis of one RCT identified that 7/38 patients in the FMT arm and 1/37 in the placebo arm achieved histologic



**Figure 2.** Forest plot of the meta-analysis of clinical remission and faecal microbiota transplantation [FMT] in ulcerative colitis including available cohort studies to date. The pooled proportions with 95% confidence intervals [CIs] were calculated using the random effects model [diamond]. The filled squares represent the studies in relation to their weights. In this meta-analysis, four case-control studies [Kump *et al.* 2015, Scaldaferri *et al.* 2015, Pai *et al.* 2016, and Ishikawa *et al.* 2017] were included as cohorts [data from controls was removed] as the software did not allow the combination of one and two groups comparison analyses.



**Figure 3.** Forest plot of the meta-analysis of clinical remission and faecal microbiota transplantation [FMT] in ulcerative colitis including four randomised controlled trials [RCTs] available to date. The pooled odds ratios [ORs] with 95% confidence intervals [CIs] were calculated using the random effects model [diamond]. The filled squares represent the studies in relation to their weights.

remission.<sup>9</sup> Only two of the 24 identified cohort studies of FMT in UC reported histologic data.<sup>36,38</sup> Only one case report of FMT in CD provided histologic outcomes.<sup>57</sup> In the one pouchitis study that reported histologic outcomes, none of five patients achieved a PDAI histologic subscore of 0.<sup>65</sup>

### 3.8. Paediatric vs adult populations


Subgroup analyses were performed for a number of variables thought to be of importance [Table A6, available as Supplementary data at ECCO-JCC online], including population age [paediatric vs adult]. There were six cohort studies assessing 34 patients in paediatric UC and only two cohort studies assessing 13 patients in paediatric CD. The pooled estimate proportion of patients that achieved clinical remission was 23% [95% CI = 7–51%; Cochran’s Q,  $p = 0.171$ ;  $I^2 = 35\%$ ] for paediatric UC and 34%

[95% CI = 24–46%; Cochran’s Q,  $p = 0.001$ ;  $I^2 = 58\%$ ] for adult UC. For CD, the pooled estimate of clinical remission was 54% [95% CI = 28–78%; Cochran’s Q,  $p = 0.853$ ;  $I^2 = 0\%$ ] in paediatric CD patients and 46% [95% CI = 18–77%; Cochran’s Q,  $p = 0.017$ ;  $I^2 = 71\%$ ] in adult CD patients. No completed randomised controlled trials have been published assessing FMT in paediatric IBD.

### 3.9. FMT methodology

The included studies varied substantially in FMT infusion methodology/protocol, including route of administration, number and frequency of infusions, dosage of stool per infusion, preparation of inoculum [fresh or frozen], antibiotic pre-treatment, bowel lavage, and FMT donor source [related or unrelated].





**Figure 4.** Forest plot of the meta-analysis of clinical remission and faecal microbiota transplantation [FMT] in Crohn's disease including available cohort studies to date. The pooled proportions with 95% confidence intervals [CIs] were calculated using the random effects model [diamond]. The filled squares represent the studies in relation to their weights.

Subgroup analyses of the cohort studies [Table A6] showed that route of administration might play a significant role in clinical remission among UC patients, as the pooled proportion of UC patients receiving upper gastrointestinal infusions was 17% [95% CI = 8–32%; Cochran's Q,  $p = 0.604$ ;  $I^2 = 0\%$ ] whereas the pooled proportion of UC patients receiving lower gastrointestinal infusions was 36% [95% CI = 24–50%; Cochran's Q,  $p = 0.004$ ;  $I^2 = 57\%$ ]. Further subgroup analyses by number of infusions showed that the pooled proportion of UC patients receiving a high number of infusions [ $> 10$  infusions] that achieved clinical remission was 49% [95% CI = 21–77%; Cochran's Q,  $p = 0.246$ ;  $I^2 = 29\%$ ], which was considerably higher than in those UC patients who received  $\leq 10$  infusions [pooled proportion = 27%, 95% CI = 17–40%; Cochran's Q,  $p = 0.001$ ;  $I^2 = 58\%$ ]. Although the pooled proportion of UC patients receiving fresh infusions that achieved clinical remission [28%, 95% CI = 15–46%; Cochran's Q,  $p = 0.001$ ;  $I^2 = 63\%$ ] was less than with frozen infusions [36%, 95% CI = 13–67%; Cochran's Q,  $p = 0.045$ ;  $I^2 = 63\%$ ], this was likely confounded by association with an increased number of infusions. Further, the pooled proportion of UC patients who received an antibiotic course before FMT and achieved clinical remission was 33% [95% CI = 17–54%; Cochran's Q,  $p = 0.026$ ;  $I^2 = 58\%$ ], whereas the proportion in UC patients who did not receive an antibiotic course pre-FMT was 28% [95% CI = 16–44%; Cochran's Q,  $p = 0.002$ ;  $I^2 = 61\%$ ]. The relevance of the other subgroup analyses findings is uncertain, given the small number of studies and patients. Only a few studies used a multi-donor infusion,<sup>11,12,50</sup> but all reported some degree of clinical and endoscopic benefit [clinical remission rates 15–50%, endoscopic remission or response rates 10–55%] despite varying number of infusions [Tables 2, 3].

### 3.10. Safety

The majority of studies did not report major adverse events or serious adverse events that were deemed clinically related to FMT therapy. Most reported adverse events were transient minor gastrointestinal complaints [bloating, diarrhoea, flatulence, abdominal pain/cramping, borborygmus] and/or fever.<sup>31-35,44,46-48,52,54,58-61,63</sup> The lack of a control arm in most of the studies makes it difficult to determine to what degree symptoms are specifically attributable to FMT. Nasogastric FMT infusion was associated with aspiration pneumonia in one study,<sup>42</sup> prompting a switch to lower gastrointestinal [GI] administration. A few reports of disease worsening<sup>40,49,55</sup> were identified, including one of cytomegalovirus [CMV] colitis in a

patient who self-administered unscreened FMT.<sup>21</sup> One death due to toxic megacolon and sepsis was reported.<sup>53</sup>

The RCTs found no difference between FMT and control arms in terms of minor or serious adverse events or disease worsening [Table 6], though it must be noted that these studies were not powered to specifically assess for safety.

### 3.11. Microbiological analyses

Microbiota analysis was performed in 17/41 UC, 4/11 CD, and 3/4 pouchitis studies [Table A7, available as Supplementary data at ECCO-JCC online]. Most studies assessed luminal [faecal] samples with only a limited number analysing mucosal [biopsy] samples.<sup>33,63,66,67</sup> A range of studies commented on recipient microbiota changes after FMT, with increased  $\alpha$ -diversity or richness<sup>9,11,38,42,48,50,61,66</sup> and a shift towards the donor profile, which in some cases was associated with colonisation by donor-derived taxa, though this was reported in patients both with clinical benefit<sup>10,26,32,35,57,60,65</sup> and without improvement.<sup>33,36</sup> Some studies did report that the increase in recipient microbial diversity after FMT was greater in responders relative to non-responders.<sup>11,42,61,66</sup> In particular, the study by Paramsothy *et al.*<sup>11,66</sup> found that recipient microbial diversity at baseline predicted response to FMT, that microbial diversity increased with FMT, and that this persisted for 8 weeks following FMT. In this study, the multi-donor FMT batches used for the FMT infusions had substantially greater microbial diversity relative to the individual donors. A correlation between increased donor microbial diversity and therapeutic success of FMT in UC has been identified in some studies<sup>42,68</sup> but not others.<sup>51</sup> In the RCT by Moayyedi *et al.*,<sup>9</sup> there was a trend towards a difference in recipient outcomes based on particular donor, with improved outcomes noted in patients receiving infusions derived from donor B [ $p = 0.06$ ]. A variety of taxa were reported to be associated with both FMT in IBD in general, and more specifically with therapeutic outcomes in IBD patients, across the identified studies.

## 4. Discussion

This paper represents an up-to-date systematic review and meta-analysis of FMT in IBD, incorporating both full text and abstract studies. There are almost three times as many studies included in this paper compared with previous systematic reviews and/or meta-analyses on the topic,<sup>7,8,69,70</sup> illustrating the rapid growth in global research interest and activity with regards to FMT for IBD, including the first randomised trials of FMT in IBD.<sup>9-12</sup> However, the overall quality of the studies remains low, primarily consisting of either case reports/series or small cohort studies of limited duration. Additionally, there remains considerable heterogeneity among the studies in terms of design, with conflicting treatment protocols [route of administration, number and frequency of infusions, antibiotic pre-treatment, bowel lavage] along with differing and often highly variable and/or poorly defined efficacy endpoints.

FMT in UC appears very promising, especially with multiple infusions administered via the lower gastrointestinal tract. An earlier meta-analysis,<sup>8</sup> assessing only UC cohort studies, identified 79 patients with a pooled proportion achieving clinical remission of 22% [95% CI = 10.4–40.8%]. The current meta-analysis identified 24 UC cohort studies assessing 307 patients, with a pooled proportion of patients that achieved clinical remission of 33% [95% CI = 23–43%]. Furthermore, four RCTs reporting on 140 FMT-treated UC patients were analysed. Meta-analysis of all four studies produced a significant association [P-OR = 2.89, 95% CI = 1.36–6.13,  $p$

**Table 6.** Adverse event data of faecal microbiota transplant [FMT] in ulcerative colitis randomised controlled trials [RCTs].

Author	Minor adverse events	Serious adverse event
Moayeddi <i>et al.</i> , 2015 <sup>9</sup>	Not specified	3/38 [8%] vs 2/37 [5%] [ $p = 1.0$ ]: instead of, 2 FMT patients had change in diagnosis to Crohn's colitis, 1 FMT patient had <i>Clostridium difficile</i> infection
Rossen <i>et al.</i> , 2015 <sup>10</sup>	78.3% of donor arm vs 64% placebo [ $p = 0.28$ ], most commonly transient borborygmus or increase in stool frequency; 2 patients in FMT arm vomited, 2 patients in FMT arm had transient fever	2 FMT, 2 control: instead of, 1 admitted for suspicion of small bowel perforation [noted to have small bowel CD], 1 with severe cytomegalovirus [autologous arm], 1 with cervical cancer requiring surgery, 1 severe abdominal pain requiring admission with spontaneous recovery
Paramsothy <i>et al.</i> , 2017 <sup>11</sup>	78% in FMT arm vs 83% in placebo [ $p = NS$ ], mostly self-limiting GI complaints [abdominal pain, bloating, flatulence]	3 worsening colitis requiring hospitalisation [2 FMT including 1 colectomy, 1 placebo]
Costello <i>et al.</i> , 2017 <sup>12</sup>	Not specified	3 FMT group, 2 control: instead of, 3 worsening colitis [2 autologous arm], 1 <i>Clostridium difficile</i> colitis requiring colectomy, 1 pneumonia

NS, not significant; GI, gastrointestinal.

= 0.006] between FMT and UC clinical remission induction [Figure 3]. Further sensitivity analyses showed that removal of the smallest study<sup>10</sup> [which used only two infusions and administered them via an upper gastrointestinal infusion, as opposed to the other studies] resulted in an even more highly significant association between FMT and clinical remission in UC patients [P-OR of 4.05, 95% CI = 2.08–7.89,  $p = < 0.001$ ] [Figure A3]. This, along with subgroup analyses of the UC cohort studies, suggests that multiple infusions [and possibly lower gastrointestinal administration] increases the likelihood of remission in UC patients treated with FMT, though the precise number required varied substantially between studies, remains to be defined, and likely is donor-and recipient-dependent.

Regarding the role of FMT in CD, the pooled proportion of patients that achieved clinical remission presented in the current meta-analysis [52%] is slightly lower than the figure reported in the previous meta-analysis<sup>8</sup> [pooled proportion = 60.5%, 95% CI = 28.4%–85.6%]. As previously highlighted by these authors, however, the CD results should be interpreted with caution, as the confidence intervals remain wide and the pooled effect size may be inflated due to the variability of methodology among individual studies and the still limited data. This is further supported by the publications bias observed in the current meta-analysis on clinical remission and FMT in CD patients. Furthermore, it is known that clinical remission does not correlate with endoscopic outcomes in CD. Of note, in the only CD cohort study to report endoscopic outcomes, no patient experienced endoscopic remission.<sup>42</sup>

There remain major limitations in the available literature of this developing field. There are insufficient data to support FMT for other indications besides CDI,<sup>71,72</sup> with no randomised trials published or presented to date outside UC. Even within UC, the existing studies are relatively small in size [largest 81 patients], and where FMT would be best placed in the therapeutic algorithm is unclear given the growing number of biologics<sup>73</sup> and emerging targeted small molecule therapies.<sup>74,75</sup> Long-term follow-up data regarding FMT efficacy/durability and safety in IBD are lacking. The available data suggest that disease relapse will invariably occur [though the durability and impact of number of infusions are poorly defined] and some form of maintenance therapy is required. However, almost all studies performed to date have assessed the role of FMT in remission induction for IBD, with a paucity of literature on the potential of FMT as a maintenance therapy<sup>38</sup> once remission is established. The safety data from the available literature are reassuring though limited by study size and follow-up period. There have been reports from the FMT in IBD and CDI co-infection literature, of disease flare following

FMT.<sup>76,77</sup> However, these must be considered in the context of an absence of a control arm [to account for gastrointestinal symptoms after FMT in non-IBD patients], difficulty in distinguishing colitis symptoms attributable to IBD as opposed to CDI, along with variable endoscopic mucosal activity assessment. In this context, Fischer *et al.*<sup>77</sup> reported improvement in clinician assessment of IBD activity after FMT for CDI in 31/67 [46%] and worsening in 12/67 [18%]. Additionally, there are few well-conducted microbiological studies on the effect of FMT on the intestinal microbiota in IBD. These are clearly required if we are to better understand the underlying mechanism of action and microbial predictors of therapeutic outcome, both beneficial and detrimental. Most studies to date have included small numbers of patients and focused primarily on microbial composition and not functional/metabolic consequences. Taxonomic changes identified to date associated with FMT and therapeutic benefit, are variable and inconsistent [Table A7]. There exist inherent differences among donors, regardless of whether they are related or unrelated/anonymous, and the clinical and microbiological factors that are of importance in donor outcomes remain largely undefined.

The American Gastroenterological Association [AGA] has recently set up an FMT registry [http://www.gastro.org/patient-care/registries-studies/fmt-registry] to help characterise long-term outcomes of FMT [though this is primarily directed towards *Clostridium difficile* infection], and there are many new studies of FMT in IBD in progress [clinicaltrials.gov] that will hopefully address these issues. Future directions should also include more specific and targeted allied microbiological studies to try to identify donor and recipient factors of importance, which may potentially facilitate progress to donor-recipient matching, and ultimately defined microbial consortia based on recipient phenotype, along with ongoing development of capsule therapy with directed small bowel or colonic release.

## Funding

No funding source was associated with the production of this manuscript. SP is supported by a Postgraduate Scholarship from the National Health and Medical Research Council [NHMRC], Australia. NCR is supported by an Early Career Fellowship from the NHMRC. NOK is supported by a Career Development Fellowship from the Cancer Institute NSW, Australia.

## Conflict of Interest

The authors have no financial or potential competing interest or affiliation with any institution, organisation, or company relating to the manuscript.

## Supplementary Data

Supplementary data are available at *ECCO-JCC* online.

## References

- van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent *Clostridium difficile*. *N Engl J Med* 2013;368:407–15.
- Kassam Z, Lee CH, Yuan Y, Hunt RH. Fecal microbiota transplantation for *Clostridium difficile* infection: systematic review and meta-analysis. *Am J Gastroenterol* 2013;108:500–8.
- Borody TJ, Khoruts A. Fecal microbiota transplantation and emerging applications. *Nat Rev Gastroenterol Hepatol* 2011;9:88–96.
- Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. *Surgery* 1958;44:854–9.
- Bennet JD, Brinkman M. Treatment of ulcerative colitis by implantation of normal colonic flora. *Lancet* 1989;1:164.
- Smith MB, Kelly C, Alm EJ. Policy: How to regulate faecal transplants. *Nature* 2014;506:290–1.
- Anderson JL, Edney RJ, Whelan K. Systematic review: faecal microbiota transplantation in the management of inflammatory bowel disease. *Aliment Pharmacol Ther* 2012;36:503–16.
- Colman RJ, Rubin DT. Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. *J Crohns Colitis* 2014;8:1569–81.
- Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. *Gastroenterology* 2015;149:102–9 e6.
- Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. *Gastroenterology* 2015;149:110–8.e4.
- Paramsothy S, Kamm MA, Kaakoush NO, et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. *Lancet* 2017;389:1218–28.
- Costello S, Waters O, Bryant R, et al. Short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomised controlled trial. In: 12th Congress of ECCO; February 15–18, 2017; Barcelona, Spain.
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *BMJ* 2009;339:b2535.
- Furlan AD, Pennick V, Bombardier C, van Tulder M; Editorial Board, Cochrane Back Review Group. 2009 updated method guidelines for systematic reviews in the Cochrane Back Review Group. *Spine* 2009;34:1929–41.
- Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology [MOOSE] group. *JAMA* 2000;283:2008–12.
- Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale [NOS] for assessing the quality of nonrandomised studies in meta-analyses. Volume 2017. [http://www.ohri.ca/programs/clinical\\_epidemiology/oxford.asp](http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp). Accessed March 1, 2017.
- Higgins JP, Altman DG, Gøtzsche PC, et al.; Cochrane Bias Methods Group; Cochrane Statistical Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ* 2011;343:d5928.
- Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002;21:1539–58.
- Borody TJ, George L, Andrews P, et al. Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome? *Med J Aust* 1989;150:604.
- Borody T, Campbell J, Torres M, et al. Reversal of idiopathic thrombocytopenic purpura [ITP] with fecal microbiota transplantation [FMT]. *Am J Gastroenterol* 2011;106:S352.
- Hohmann EL, Ananthakrishnan AN, Deshpande V. Case Records of the Massachusetts General Hospital. Case 25-2014. A 37-year-old man with ulcerative colitis and bloody diarrhea. *N Engl J Med* 2014;371:668–75.
- Vandenplas Y, Veereman G, van der Werff Ten Bosch J, et al. Fecal microbial transplantation in early-onset colitis: caution advised. *J Pediatr Gastroenterol Nutr* 2015;61:e12–4.
- Seth AK, Rawal P, Bagga R, Jain P. Successful colonoscopic fecal microbiota transplantation for active ulcerative colitis: First report from India. *Indian J Gastroenterol* 2016;35:393–5.
- Kumagai H, Yokoyama K, Imagawa T, et al. Failure of fecal microbiota transplantation in a three-year-old child with severe refractory ulcerative colitis. *Pediatr Gastroenterol Hepatol Nutr* 2016;19:214–20.
- Ni X, Fan S, Zhang Y, et al. Coordinated hospital-home fecal microbiota transplantation via percutaneous endoscopic cecostomy for recurrent steroid-dependent ulcerative colitis. *Gut Liver* 2016;10:975–80.
- Shimizu H, Arai K, Abe J, et al. Repeated fecal microbiota transplantation in a child with ulcerative colitis. *Pediatr Int* 2016;58:781–5.
- Borody T, Leis S, McGrath K, et al. Treatment of chronic constipation and colitis using human probiotic infusions. In: Probiotics, Prebiotics and New Foods Conference; September 2–4, 2001; Rome: Universita Urbaniana.
- Borody TJ, Warren EF, Leis S, Surace R, Ashman O. Treatment of ulcerative colitis using fecal bacteriotherapy. *J Clin Gastroenterol* 2003;37:42–7.
- Borody T, Wettstein A, Campbell J, et al. Fecal microbiota transplantation in ulcerative colitis: Review of 24 years experience. *Am J Gastroenterol* 2012;107:S665.
- Shah R, Robinson L, Herrera HR, et al. Human probiotic infusion [HPI] in ulcerative colitis – ‘patient’s perceptions and predictors of efficacy’. *Gastroenterology* 2012;142:S253.
- Brandt L, Aroniadis O, Greenberg A, et al. Safety of fecal microbiota transplantation [FMT] in immunocompromised [IC] patients with inflammatory bowel disease [IBD]. *Am J Gastroenterol* 2013;108:S556.
- Angelberger S, Reinisch W, Makrathathis A, et al. Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. *Am J Gastroenterol* 2013;108:1620–30.
- Kump PK, Gröchenig HP, Lackner S, et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. *Inflamm Bowel Dis* 2013;19:2155–65.
- Kunde S, Pham A, Bonczyk S, et al. Safety, tolerability, and clinical response after fecal transplantation in children and young adults with ulcerative colitis. *J Pediatr Gastroenterol Nutr* 2013;56:597–601.
- Cui B, Li P, Xu L, et al. Step-up fecal microbiota transplantation strategy: a pilot study for steroid-dependent ulcerative colitis. *J Transl Med* 2015;13:298.
- Damman CJ, Brittnacher MJ, Westerhoff M, et al. Low level engraftment and improvement following a single colonoscopic administration of fecal microbiota to patients with ulcerative colitis. *PLoS One* 2015;10:e0133925.
- Karolewska-Bochenek K, Lazowska-Przeorek I, Grzesiowski P, et al. Fecal microbiota transplantation in refractory pediatric UC—Preliminary data. *J Crohns Colitis* 2015;9:S294.
- Kellermayer R, Nagy-Szakal D, Harris RA, et al. Serial fecal microbiota transplantation alters mucosal gene expression in pediatric ulcerative colitis. *Am J Gastroenterol* 2015;110:604–6.
- Kump PK, Wurm P, Gröchenig HP, et al. Impact of antibiotic treatment before faecal microbiota transplantation [FMT] in chronic active ulcerative colitis. *United European Gastroenterol J* 2015;3(5 Suppl):A437.
- Scalaferrri F, Pecere S, Bruno G, et al. An open-label, pilot study to assess feasibility and safety of fecal microbiota transplantation in patients with mild-moderate ulcerative colitis: Preliminary results. *J Crohns Colitis* 2015;9:S278.
- Suskind DL, Singh N, Nielson H, Wahbeh G. Fecal microbial transplant via nasogastric tube for active pediatric ulcerative colitis. *J Pediatr Gastroenterol Nutr* 2015;60:27–9.
- Vermeire S, Joossens M, Verbeke K, et al. Donor species richness determines faecal microbiota transplantation success in inflammatory bowel disease. *J Crohns Colitis* 2016;10:387–94.
- Wei Y, Zhu W, Gong J, et al. Fecal microbiota transplantation improves the quality of life in patients with inflammatory bowel disease. *Gastroenterol Res Pract* 2015;2015:517597.

44. Ren R, Sun G, Yang Y, *et al.* [A pilot study of treating ulcerative colitis with fecal microbiota transplantation]. *Zhonghua Nei Ke Za Zhi* 2015;54:411–5.
45. Karakan T, Ibis M, Cindoruk Z, *et al.* Faecal microbiota transplantation as a rescue therapy for steroid-dependent and/or non-responsive patients with ulcerative colitis: a pilot study. In: 11th Congress of the European Crohn's and Colitis Organisation, March 16–19, 2016; Amsterdam, The Netherlands.
46. Goyal A, Chu A, Calabro K, *et al.* Safety and efficacy of fecal microbiota transplant in children with inflammatory bowel disease. *J Pediatr Gastroenterol Nutr* 2016;63:S212.
47. Laszlo M, Ciobanu L, Andreica V, Pascu O. Fecal transplantation indications in ulcerative colitis. Preliminary study. *Chujul Med* 2016;89:224–8.
48. Wei Y, Gong J, Zhu W, *et al.* Pectin enhances the effect of fecal microbiota transplantation in ulcerative colitis by delaying the loss of diversity of gut flora. *BMC Microbiol* 2016;16:255.
49. Pai N, Popov J, Lee C. A randomized, placebo-controlled trial of fecal microbial transplantation for pediatric ulcerative colitis [Pedifetch Trial]. *J Pediatr Gastroenterol Nutr* 2016;63:S79–80.
50. Jacob V, Crawford C, Cohen-Mekelburg S, *et al.* Fecal microbiota transplantation via colonoscopy is safe and effective in active ulcerative colitis. In: *Advances in Inflammatory Bowel Diseases*; December 8–10, 2016; Orlando, FL.
51. Nishida A, Imaeda H, Ohno M, *et al.* Efficacy and safety of single fecal microbiota transplantation for Japanese patients with mild to moderately active ulcerative colitis. *J Gastroenterol* 2017;52:476–82.
52. Zhang T, Cui B, Li P, *et al.* Short-term surveillance of cytokines and C-reactive protein cannot predict efficacy of fecal microbiota transplantation for ulcerative colitis. *PLoS One* 2016;11:e0158227.
53. Grewal CS, Sood A, Mehta V, *et al.* Role of fecal microbiota transplantation in patients with steroid dependant ulcerative colitis. *Am J Gastroenterol* 2016;111:S1252–3.
54. Ishikawa D, Sasaki T, Osada T, *et al.* Changes in intestinal microbiota following combination therapy with fecal microbial transplantation and antibiotics for ulcerative colitis. *Inflamm Bowel Dis* 2017;23:116–25.
55. Swaminath A. The power of poop: patients getting ahead of their doctors using self-administered fecal transplants. *Am J Gastroenterol* 2014;109:777–8.
56. Gordon H, Harbord M. A patient with severe Crohn's colitis responds to faecal microbiota transplantation. *J Crohns Colitis* 2014;8:256–7.
57. Kao D, Hotte N, Gillevet P, Madsen K. Fecal microbiota transplantation inducing remission in Crohn's colitis and the associated changes in fecal microbial profile. *J Clin Gastroenterol* 2014;48:625–8.
58. Kahn SA, Goepfing SR, Vaughn BP, *et al.* Tolerability of colonoscopic fecal microbiota transplantation in IBD. *Gastroenterology* 2014;146:S581.
59. Cui B, Feng Q, Wang H, *et al.* Fecal microbiota transplantation through mid-gut for refractory Crohn's disease: safety, feasibility, and efficacy trial results. *J Gastroenterol Hepatol* 2015;30:51–8.
60. Suskind DL, Brittnacher MJ, Wahbeh G, *et al.* Fecal microbial transplant effect on clinical outcomes and fecal microbiome in active Crohn's disease. *Inflamm Bowel Dis* 2015;21:556–63.
61. Vaughn BP, Vatanen T, Allegretti JR, *et al.* Increased intestinal microbial diversity following fecal microbiota transplant for active Crohn's disease. *Inflamm Bowel Dis* 2016;22:2182–90.
62. Fang S, Kraft CS, Dhere T, *et al.* Successful treatment of chronic pouchitis utilizing fecal microbiota transplantation [FMT]: a case report. *Int J Colorectal Dis* 2016;31:1093–4.
63. Landy J, Walker AW, Li JV, *et al.* Variable alterations of the microbiota, without metabolic or immunological change, following faecal microbiota transplantation in patients with chronic pouchitis. *Sci Rep* 2015;5:12955.
64. El-Nachef N, Lucey K, Somsouk M, *et al.* Fecal microbiota transplant improves symptoms in patients with pouchitis and induces changes in the microbiome: Preliminary results of an open label trial. *Gastroenterology* 2016;150:S544.
65. Stallmach A, Lange K, Buening J, Sina C, Vital M, Pieper DH. Fecal microbiota transfer in patients with chronic antibiotic-refractory pouchitis. *Am J Gastroenterol* 2016;111:441–3.
66. Paramsothy S, Kaakoush N, Kamm MA, *et al.* Faecal microbiota transplantation [FMT] in ulcerative colitis [UC] is associated with specific bacterial changes: Stool and colonic mucosa 16S microbiota analysis from the randomised controlled FOCUS Study. In: United European Gastroenterology Week; October 15–19, 2016; Vienna.
67. Fuentes S, Rossen NG, van der Spek MJ, *et al.* Microbial shifts and signatures of long-term remission in ulcerative colitis after faecal microbiota transplantation. *ISME J* 2017, Apr 11. doi: 10.1038/ismej.2017.44. [Epub ahead of print.]
68. Kump PK, Wurm P, Grochenig HP, *et al.* Clinical response to fecal microbiota transplantation in chronic active ulcerative colitis depends on the taxonomic composition of the donor microbiota. In: United European Gastroenterology Week; October 15–19, 2016; Vienna.
69. Rossen NG, MacDonald JK, de Vries EM, *et al.* Fecal microbiota transplantation as novel therapy in gastroenterology: A systematic review. *World J Gastroenterol* 2015;21:5359–71.
70. Sha S, Liang J, Chen M, *et al.* Systematic review: faecal microbiota transplantation therapy for digestive and nondigestive disorders in adults and children. *Aliment Pharmacol Ther* 2014;39:1003–32.
71. König J, Siebenhaar A, Högenauer C, *et al.* Consensus report: faecal microbiota transfer clinical applications and procedures. *Aliment Pharmacol Ther* 2017;45:222–39.
72. Cammarota G, Ianiro G, Tilg H, *et al.* European consensus conference on faecal microbiota transplantation in clinical practice. *Gut* 2017;66:569–80.
73. Feagan BG, Rutgeerts P, Sands BE, *et al.*; GEMINI 1 Study Group. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med* 2013;369:699–710.
74. Sandborn WJ, Ghosh S, Panes J, *et al.*; Study A3921063 Investigators. Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. *N Engl J Med* 2012;367:616–24.
75. Sandborn WJ, Feagan BG, Wolf DC, *et al.*; TOUCHSTONE Study Group. Ozanimod induction and maintenance treatment for ulcerative colitis. *N Engl J Med* 2016;374:1754–62.
76. Khoruts A, Rank KM, Newman KM, *et al.* Inflammatory bowel disease affects the outcome of fecal microbiota transplantation for recurrent *Clostridium difficile* infection. *Clin Gastroenterol Hepatol* 2016;14:1433–8.
77. Fischer M, Kao D, Kelly C, *et al.* Fecal microbiota transplantation is safe and efficacious for recurrent or refractory *Clostridium difficile* infection in patients with inflammatory bowel disease. *Inflamm Bowel Dis* 2016;22:2402–9.